ABSTRACT
Objective To explore RIZ1 mRNA expression level in different subtypes and risk classification groups of the patients with myelodysplastic syndromes (MDS) and to analyze the correlation between the clinical features and RIZ1 mRNA expression. Methods A total of 46 newly diagnosed as MDS patients and 10 healthy controls who were the donors of hematopoietic stem cell transplantation from Chuiyangliu Hospital Affiliated to Tsinghua University and the Second Hospital of Shanxi Medical University between January 2014 and December 2017 were collected. The real time fluorescence quantitative polymerase chain reaction (RT-PCR) was used to detect the expression level of RIZ1 mRNA in bone marrow cells from MDS patients and the healthy controls. Results Compared with the healthy control group, the relative expression level of RIZ1 mRNA in MDS patients was decreased [the median (P25, P75):1.003 (0.895, 1.812) vs. 0.557 (0.333, 0.815)], and the difference was statistically significant (Z= -2.991, P= 0.0003). According tothe World Health Organization (WHO) classification criteria, compared with the healthy control group, the relative expression of RIZ1 mRNA in refractory anemia/refractory anemia with ring sideroblasts/refractory cytopenia with multiple dysplasia (RA/RAS/RCMD), refractory anemia with excess blasts Ⅰ (RAEB-Ⅰ), RAEB-Ⅱand MDS transformed into acute myeloid leukemia (MDS/AML) groups had statistically significant differences (χ2= 19.500, P< 0.01). Further pairwise comparison showed that the relative expression level of RIZ1 mRNA in RAEB-Ⅰ, RAEB-Ⅱand MDS/AML groups was lower than that in the healthy control group, and the differences were statistically significant (all P < 0.05). According to the international prognostic scoring system (IPSS), compared with the healthy control group, the expression of RIZ1 mRNA in low-risk, inter-risk-1, inter-risk-2 and high-risk group had statistical differences (χ2= 19.214, P= 0.001). Further pairwise comparison showed that the relative expression of RIZ1 mRNA in inter-risk-1, inter-risk-2 and high risk group was lower than that in the healthy control group, and the differences were statistically significant (all P<0.05). And RIZ1 mRNA expression showed a decreasing trend with the increase of disease risk grade. RIZ1 mRNA expression level had no relationship with age, gender, peripheral blood white cell count, the hemoglobin, platelet count and karyotype (all P> 0.05). Conclusion RIZ1 mRNA expression level is decreased in MDS patients, and it is different in various subtypes and risk classification. RIZ1 may involve in the pathogenesis of MDS and play an important role in the progression of MDS.
ABSTRACT
Objective The aim of this study was to analyze the expression of RIZ 1 and its association with clinicopathological factors or radiosensitivity in cervical squamous cell carcinoma.Methods 159 samples from patients with FIGO stage Ⅱb and Ⅲa cervical squamous cell carcinoma were collected and preserved be-fore radiotherapy.The expression of RIZ1 in cervical squamous cell carcinoma tissues and 20 normal cervical tis-sues was assessed by immunohistochemistry.The relationship between the RIZ1 expression and the clinicopatho-logical factors or radiosensitivity in cervical squamous cell carcinoma was analyzed by statistical analysis.Results The expression of RIZ1 protein was down-regulated in patients with cervical cancer(P<0.001).The level of RIZ1 protein expression was close related to radiosensitivity(P=0.012),FIGO staging(P=0.004),deep myo-metrial invasion(P=0.026),and pelvic lymph node metastasis(P=0.005).Logistic regression analysis showed that the high expression of RIZ1protein was an independent predictor of radiosensitivity in cervical cancer(P=0.045).Conc lusion RIZ1 may be involved in the occurrence and development process of cervical squamous cell carcinoma and regard as a candidate biomarker for the sensitivity in cervical squamous cell carcinoma in ra-diotherapy.
ABSTRACT
Objective The aim of this study was to analyze the expression of RIZ 1 and its association with clinicopathological factors or radiosensitivity in cervical squamous cell carcinoma.Methods 159 samples from patients with FIGO stage Ⅱb and Ⅲa cervical squamous cell carcinoma were collected and preserved be-fore radiotherapy.The expression of RIZ1 in cervical squamous cell carcinoma tissues and 20 normal cervical tis-sues was assessed by immunohistochemistry.The relationship between the RIZ1 expression and the clinicopatho-logical factors or radiosensitivity in cervical squamous cell carcinoma was analyzed by statistical analysis.Results The expression of RIZ1 protein was down-regulated in patients with cervical cancer(P<0.001).The level of RIZ1 protein expression was close related to radiosensitivity(P=0.012),FIGO staging(P=0.004),deep myo-metrial invasion(P=0.026),and pelvic lymph node metastasis(P=0.005).Logistic regression analysis showed that the high expression of RIZ1protein was an independent predictor of radiosensitivity in cervical cancer(P=0.045).Conc lusion RIZ1 may be involved in the occurrence and development process of cervical squamous cell carcinoma and regard as a candidate biomarker for the sensitivity in cervical squamous cell carcinoma in ra-diotherapy.
ABSTRACT
Objective To investigate the expression levels of retinoblastoma protein-interacting zinc finger gene 1 (RIZ1) in gliomas of different grades and its association with patient prognosis. Methods The expression of RIZ1 and Ki-67 in 51 glioma tissues of different grades were evaluated immunohistochemically. The correlation of RIZ1 immunoreactivity with the clinicopathological features and the prognostic value of RIZ1 in patients were analyzed. Results Immunohistochemistry results showed that RIZ1 was mainly expressed in the cytoplasm and Ki-67 was mainly located in the nuclei. We found that low grade glioma tissue had a significantly higher expression of RIZ1 compared with the high grade one ([7.55±4.39]% vs [48.83±4.34]%,P<0.000 1). There was a negative correlation between RIZ1 and Ki-67 immunoreactivity (Spearman: r=-0.813 0, P<0.000 1). It was also suggested that RIZ1 expression was negatively associated with tumor grade and patient age (P<0.05). Kaplan-Meier survival analysis revealed a positive correlation between expression of RIZ1 and progress-free survival (PFS) and overall survival (OS) of patients(P<0.000 1). Univariate analysis revealed that high RIZ1 expression and low Ki-67 expression were associated with better patient prognosis. Multivariate analysis using the Cox proportional hazards model revealed that high RIZ1 expression was significantly correlated with prognosis of patients with gliomas(P=0.000,HR=0.164,95%CI:0.071-0.378). Conclusion It is concluded that RIZ1 expression is decreased with the increase of pathological grade of gliomas, and it is associated with patients prognosis; RIZ1 may serve as a marker for treatment and prognosis prediction of gliomas.
ABSTRACT
Background and purpose:Few reports demonstrate the relation between the expression of RIZ1 which has been found to be a tumor suppressor gene recently and leukemia. This study investigated the effect of RIZ1 expression on the apoptosis of human myeloid leukemic cell lines. Methods:The expression of RIZ1 mRNA was observed in human myeloid leukemic cell lines AML193, KG-1, KG-1a, K562 and Ery-1 by reverse transcription polymerase chain reaction assay. RIZ1 was forced to express in the expression-lacking cell lines by transfecting pRIZ1 RH containing full length of RIZ1 cDNA to the cell lines. As controls, the cell lines were transfected with pcDNA3.1. The apoptotic cells were determined by using the annexin V/propidium iodide stain 24 h after transfection.Results:Among the 5 cell lines, no expression of RIZ1 mRNA had been detected in AML193 and low expression in K562. The forced expression could be found in both cell lines 24 h after transfection of pRIZ1 RH, accompanied by obviously increased apoptotic rates which were (22.7? 0.7)% in AML193 and (28.6?1.2)% in K562 compared to controls (11.7%?1.6% and 9.0%?0.8%, respectively) (P